4918-95-0

Usage

Uses

Used in Medical Industry:
4-[(DIMETHYLAMINO)METHYL]-2,6-DIISOPROPYLBENZENOL is used as a general anesthetic for inducing and maintaining anesthesia during surgical procedures. It is administered intravenously and works by enhancing the activity of the neurotransmitter GABA in the brain, leading to sedation and relaxation.
However, propofol use can have side effects, such as cardiac and respiratory depression, and it must be administered by trained medical professionals in a controlled environment to ensure patient safety.

InChI:InChI=1/C15H25NO/c1-10(2)13-7-12(9-16(5)6)8-14(11(3)4)15(13)17/h7-8,10-11,17H,9H2,1-6H3

Upstream product

• 50-00-0 formaldehyd 
• 2078-54-8 2,6-diisopropylphenol 
• 124-40-3 dimethyl amine 

Downstream Products

• 36821-89-3 4-(2,4-diamino-6-methylsulfanyl-pyrimidin-5-ylmethyl)-2,6-diisopropyl-phenol 
• 15640-40-1 bis(4-hydroxy-2,6-dimethoxyphenyl)methane 
• 27189-56-6 1-(3-Methyl-5-Tert_.Butyl-4-Hydroxyphenyl)-3-(3,5-Di-Isopropyl-4-Hydroxyphenyl)-2,2-Bis-Carbostearoxy Propane 
• 343838-92-6 5-(3,5-diisopropyl-4-methoxy-benzyl)-6-methylsulfanyl-pyrimidine-2,4-diamine 
• 36821-90-6 5-(3,5-diisopropyl-4-methoxy-benzyl)-pyrimidine-2,4-diamine 
• 59735-34-1 2,2-Bis-(4-hydroxy-3,5-diisopropyl-benzyl)-malonic acid bis-(2-dodecylsulfanyl-ethyl) ester 
• 59735-06-7 2-Cyano-2-(4-hydroxy-3,5-diisopropyl-benzyl)-3-(4-hydroxy-3,5-diisopropyl-phenyl)-propionic acid dodecyl ester 

Relevant academic research and scientific papers

Propofol analogues. Synthesis, relationships between structure and affinity at GABA(A) receptor in rat brain, and differential electrophysiological profile at recombinant human GABA(A) receptors

A number of propofol (2,6-diisopropylphenol) congeners and derivatives were synthesized and their in a vitro capability to affect GABA(A) receptors determined by the inhibition of the specific [35S]-tert- butylbicyclophosphorothionate ([35S]TBPS) binding to rat whole brain membranes. Introduction of halogen (Cl, Br, and I) and benzoyl substituents in the para position of the phenyl group resulted in ligands with higher potency at inhibiting [35S]TBPS binding. A quantitative structure - affinity relationship (QSAR) study demonstrated that affinity is enhanced by increases in lipophilicity of the ligand whereas affinity is adversely affected by increases in size of the substituent para to the phenolic hydroxyl group. Consistent with the displacement of [35S]TBPS and with the activation of GABA(A) receptors, we demonstrate that ligands displaying high affinity (i.e., 2-4, and 8) are able to increase GABA-stimulated chloride currents in oocytes expressing human GABA(A) receptors and to directly activate chloride currents in an electrophysiological assay. Among them, compound 4 showed a rather peculiar profile in the electrophysiological examination with cloned α1β2γ2 GABA(A) receptors. Indeed, compared to propofol, it displayed a much greater efficacy at potentiating GABA-elicited chloride currents, but a much lower efficacy at producing a direct activation of the chloride channel in the absence of GABA. This behavior may give to compound 4 pharmacological properties that are more similar to anxiolytic and anticonvulsant drugs than to those of general anesthetics.

Heterocyclic Spirocyclohexadienones from Substituted Phenols

Mannich bases were prepared from substituted phenols with aliphatic amines and formaldehyde.Amine exchange with N-methyl-2-naphthylamine followed by a Hofmann Martius rearrangement gave rise to o,o'-amino-hydroxy-diphenylmethane derivatives.Under cyclization conditions some of these compounds produced spirocyclohexadienones, which are the ipso analogs to the hypothetic intermediates postulated in the aminomethylation mechanism of phenols. - Keywords: Mannich Reaction; Phenol Dienone Tautomerism; Hofmann Martius Rearrangement